Subscribe
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma
Issues
2011
August 2011, Vol 2, No 5
August 2011, Vol 2, No 5
Impressive Results with New Drugs for Advanced Prostate Cancer
By
Neil Canavan
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—The potential of 2 novel agents still in clinical trials, and 1 drug that was recently approved, offer new hope to patients with metastatic castrate-resistant prostate cancer (mCRPC), a disease with a dire prognosis and few good current treatment options.
Read Article
Bevacizumab Maintenance Reduces Disease Progression Risk in Ovarian Cancer
By
Audrey Andrews
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—The “big news” in metastatic ovarian cancer presented at ASCO 2011 involved the investigational poly (ADP-ribose) polymerase (PARP) inhibitor olaparib, which prolonged progression-free survival (PFS) by nearly 4 months versus placebo.
Read Article
Emerging Regimen for Metastatic Pancreatic Cancer Has Survival Benefit, but Is It Cost-Effective?
By
Neil Canavan
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—A cost analysis presented at ASCO 2011 and performed at the University of Toronto, Odette Cancer Center, Ontario, showed that the emerging combination regimen that includes oxaliplatin (Eloxatin), irino tecan (Camptosar), fluorouracil (Adrucil) and leucovorin (FOLFIRINOX) is not cost-effective when considered within the framework of a willingness-to-pay threshold of $100,000 per quality-adjusted life-year (QALY).
Read Article
New Regimen with an Old Drug Boosts Survival in Pediatric ALL
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—The use of high-dose methotrexate (HD-MTX) has demonstrated a significant improvement in event-free survival in patients with pediatric acute lymphoblastic leukemia (ALL) at 5 years compared with the standard regimen.
Read Article
Genome-Forward Medicine in Lung Cancer
By
Caroline Helwick
ASCO Annual Meeting
August 2011, Vol 2, No 5
Chicago, IL—Whole genome sequencing was the topic of a session at the 2011 ASCO annual meeting in which specialists discussed the implications of “genome-forward medicine” in lung cancer.
Read Article
Whole-Genome Sequencing Provides Timely Diagnosis
In the Literature
August 2011, Vol 2, No 5
Whole-genome sequencing (WGS) has traditionally been an important tool in nonclinical research. Recently, however, the potential clinical value of the technique was demonstrated in a patient with acute promyelocytic leukemia (APL) that was hard to identify (Welch JS, et al. JAMA. 2011;305: 1577-1584).
Read Article
Vemurafenib Improves Survival in Metastatic Melanoma with BRAF V600E Mutation
In the Literature
August 2011, Vol 2, No 5
Results of a phase 3 trial comparing that drug with the investigational agent vemurafenib show promise for patients with BRAF V600E mutation (Chapman PB, et al. N Engl JMed. 2011; 364:2507-2516).
Read Article
No Access to Radiotherapy Cannot Explain Reduced Survival in Black Women Post–Breast Cancer Surgery
In the Literature
August 2011, Vol 2, No 5
Black women who undergo mastectomy or lumpectomy for advanced breast cancer have shorter survival duration than their white, Hispanic, and Asian counterparts, regardless of whether they undergo radiation therapy after the procedure, according to a new study (Martinez SR, et al. Cancer. Epub ahead of print. June 20, 2011).
Read Article
Combination Therapy Improves Survival in Men with Intermediate-Risk, Early-Stage Prostate Cancer
In the Literature
August 2011, Vol 2, No 5
A new large clinical trial funded by the National Cancer Institute has demonstrated the best approach to therapy for men with intermediaterisk, early-stage prostate cancer that can prolong survival.
Read Article
FDA Warns Oncologists: Thermography No Substitute for Mammography
FDA Approvals, News & Updates
August 2011, Vol 2, No 5
The FDA has issued a warning to healthcare providers against substituting breast thermography formammography in screening for breast cancer.
Read Article
Page 3 of 4
1
2
3
4
View the Latest Issue of VBCC
Read Issue
Top Trending Articles
1.
Navigating the Complex Landscape of Oral Cancer Medication
2.
Luspatercept Yields Improved Transfusion Independence Compared With Epoetin Alfa in Patients With Lower-Risk MDS
Phoebe Starr
3.
New NCCN Guidelines for CLL/SLL Include Second-Generation BTK Inhibitors
Wayne Kuznar
Home
Issues
Online First
Latest Issue
Issue Archive
Special Issues
Browse By Topic
Personalized Medicine
Economics & Value
FDA Approvals, News & Updates
COVID-19
Cholangiocarcinoma
View All Topics ›
Conference Correspondent
SABCS 2023 - HER2+ MBC
ASCO 2023 - Breast Cancer
Web Exclusives
Web Exclusive Articles
Videos
Interview with the Innovators
Prostate Cancer Diagnostics Monthly Minutes
Webinars
Quick Quizzes
Press Releases
AVBCC
Association for Value-Based Cancer Care
VBCM
Value-Based Care in Myeloma